Company: RPID
Filing Date: 2025-05-09
Form Type: 10-Q
Source: 0001380106-25-000102
Chunk: 284

Company: RAPID MICRO BIOSYSTEMS, INC.
Filing Date: 2025-05-09
Form: 10-Q
Item: Part I, Item 1
Chunk 284
---
 and has concluded that it is more likely than not that the Company will not realize the benefits of its deferred tax assets. As a result, as of both March 31, 2025 and December 31, 2024 the Company recorded a full valuation allowance against its net deferred tax assets.The Company files income tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by U.S. federal, state and international jurisdictions, where applicable. There are currently no pending tax examinations in the U.S., and the Company has not received notice of examination from any jurisdictions in the U.S.

12. Net loss per share

As of March 31, 2025, the Company had Class A common stock and Class B common stock. Both share classes have the same rights to the Company’s earnings and neither of the classes have any prior or senior rights to dividends to the other share class.

22

Table of Contents

Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share amounts):Three Months Ended March 31,20252024Numerator:Net loss$(11,263)$(13,322)Denominator:Weighted average Class A common shares outstanding—basic and diluted 39,052,83037,936,306Weighted average Class B common shares outstanding—basic and diluted 4,940,5295,309,529Total shares for EPS—basic and diluted 43,993,35943,245,835Net loss per share attributable to Class A common stockholders—basic and diluted $(0.26)$(0.31)Net loss per share attributable to Class B common stockholders—basic and diluted $(0.26)$(0.31)The Company’s potentially dilutive securities, which include stock options, restricted stock units, and common stock warrants, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:March 31,20252024Options to purchase common stock6,953,7267,111,175Unvested restricted common stock